Count | |
| 81 | |
| 112 | |
| 1 | |
| 6 | |
| 1 | |
| 3 | |
| 2 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 5 | |
| 6 | |
| 2 | |
| 2 | |
| 1 | |
| 16 | |
| 1 | |
| 1 | |
| 3 | |
| 16 | |
| 1 | |
| 1 | |
| 1 | |
| 13 | |
| 2 | |
| 1 | |
| 2 | |
| 1 | |
| 1 | |
| 1 | |
| 7 | |
| 4 | |
| 1 | |
| 1 | |
Insulin/administration & dosage/pharmacology/*therapeutic use | 2 |
| 1 | |
| 1 | |
| 1 | |
| 1 | |
| 2 | |
| 1 | |
| 2 | |
| 1 | |
| 2 | |
Insulin, Long-Acting/*administration & dosage/therapeutic use | 1 |
Insulin/administration & dosage/adverse effects/therapeutic use | 1 |
Insulin-Like Growth Factor I/*metabolism/pharmacology/therapeutic use | 1 |
Insulin-Like Growth Factor I/adverse effects/*therapeutic use | 1 |
Insulin, Isophane/chemical synthesis/*metabolism/therapeutic use | 1 |
Insulin-Like Growth Factor I/*genetics/metabolism/therapeutic use | 1 |
Insulin/adverse effects/*analogs & derivatives/blood/*therapeutic use | 1 |
Insulin-Like Growth Factor I/adverse effects/analysis/*therapeutic use | 1 |
| 4 | |
| 15 | |
| 170 | |
| 47 | |
| 214 | |
| 3 | |
| 33 | |
| 22 | |
| 173 | |
| 19 | |
| 2 | |
| 79 | |
| 52 | |
| 2 | |
| 76 | |
| 1 | |
| 1 | |
| 8 | |
| 1 | |
| 2 | |
| 1 | |
| 45 | |
| 13 | |
| 9 | |
| 30 | |
| 195 | |
| 3 | |
| 1 | |
| 1 | |
| 1 | |
| 280 | |
| 140 | |
| 1 | |
| 1 | |
| 12 | |
| 665 | |
| 62 | |
| 1 | |
| 2 | |
| 1 | |
| 4 | |
| 1 | |
| 10 | |
| 4 | |
| 26 | |